Board of Scientific Counselors, National Center for Injury Prevention and Control, (BSC, NCIPC), 32934-32935 [2021-13119]
Download as PDF
<![CDATA[
32934
Federal Register / Vol. 86, No. 118 / Wednesday, June 23, 2021 / Notices
vaccine, dengue vaccine, ebola vaccine,
hepatitis vaccines, herpes zoster
vaccines, influenza vaccines,
orthopoxvirus vaccine, pneumococcal
vaccine, rabies vaccine and tickborne
encephalitis vaccine. Recommendation
votes on dengue vaccine, ebola vaccine,
influenza vaccines and rabies vaccine
are scheduled. Vaccines for Children
(VFC) votes on dengue vaccine and
influenza vaccines are scheduled.
Agenda items are subject to change as
priorities dictate. For more information
on the meeting agenda visit https://
www.cdc.gov/vaccines/acip/meetings/
meetings-info.html.
Meeting Information: The meeting
will be webcast live via the World Wide
Web; for more information on ACIP
please visit the ACIP website: https://
www.cdc.gov/vaccines/acip/.
jbell on DSKJLSW7X2PROD with NOTICES
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Oral Public Comment: This meeting
will include time for members of the
public to make an oral comment. Oral
public comment will occur before any
scheduled votes including all votes
relevant to the ACIP’s Affordable Care
Act and Vaccines for Children Program
roles. Priority will be given to
individuals who submit a request to
make an oral public comment before the
meeting according to the procedures
below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment at the June 23–25,
2021, ACIP meeting must submit a
request at https://www.cdc.gov/vaccines/
acip/meetings/ no later than 11:59 p.m.,
VerDate Sep<11>2014
17:13 Jun 22, 2021
Jkt 253001
EDT, June 18, 2021, according to the
instructions provided.
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a lottery to
determine the speakers for the
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
by June 21, 2021. To accommodate the
significant interest in participation in
the oral public comment session of
ACIP meetings, each speaker will be
limited to 3 minutes, and each speaker
may only speak once per meeting.
Written Public Comment: The docket
will be opened to receive written
comments on June 1, 2021. Written
comments must be received on or before
June 25, 2021.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–13120 Filed 6–22–21; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—CE21–006:
Rigorously Evaluating Programs and
Policies To Prevent Child Sexual
Abuse (CSA); Amended Notice of
Meeting
Notice is hereby given of a change in
the meeting of the Disease, Disability,
and Injury Prevention and Control
Special Emphasis Panel (SEP)—CE21–
006: Rigorously Evaluating Programs
and Policies to Prevent Child Sexual
Abuse (CSA); July 13–14, 2021, 8:30
a.m.–5:00 p.m., EDT.
The videoconference meeting was
published in the Federal Register on
March 29, 2021, Volume 86, Number 58,
page 16369.
The meeting is being amended to
update the contact person and should
read as follows:
Frm 00053
Fmt 4703
Aisha Wilkes, M.P.H., Scientific Review
Officer, National Center for Injury
Prevention and Control, CDC, 4770
Buford Highway NE, Mailstop S106–9,
Atlanta, Georgia 30341, Telephone:
(404) 639–6473; Email: awilkes@
cdc.gov.
The meeting is closed to the public.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–13121 Filed 6–22–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors,
National Center for Injury Prevention
and Control, (BSC, NCIPC)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
BILLING CODE 4163–18–P
PO 00000
FOR FURTHER INFORMATION CONTACT:
Sfmt 4703
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
for the Board of Scientific Counselors,
National Center for Injury Prevention
and Control (BSC, NCIPC). This meeting
is partially open to the public. There
will be 15 minutes allotted for public
comments at the end of the open session
from 11:40 a.m., to 11:55 p.m., EDT.
DATES: The meeting will be held on July
29, 2021, from 10:00 a.m. to 12:00 p.m.,
EDT (OPEN); and from 12:30 p.m., to
4:15 p.m., EDT (CLOSED).
ADDRESSES: Open Session: Webinar,
Atlanta, Georgia. All participants must
register using the link provided to
attend the open meeting: https://
dceproductions.zoom.us/webinar/
register/wn_cz3nu0zfsg29fiojefau8q.
Closed Session: Teleconference.
FOR FURTHER INFORMATION CONTACT:
Gwendolyn H. Cattledge, Ph.D.,
M.S.E.H., Deputy Associate Director for
Science, NCIPC, CDC, 4770 Buford
Highway NE, Mailstop S106–9, Atlanta,
SUMMARY:
E:\FR\FM\23JNN1.SGM
23JNN1
jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 118 / Wednesday, June 23, 2021 / Notices
GA 30341, Telephone: (770) 488–3953;
Email: NCIPCBSC@cdc.gov.
SUPPLEMENTARY INFORMATION: Portions
of the meeting as designated above will
be closed to the public in accordance
with provisions set forth in Section
552b(c)(4) and (6), Title 5 U.S.C., and
the Determination of the Director,
Strategic Business Initiatives Unit,
Office of the Chief Operating Officer,
CDC, pursuant to Public Law 92–463 (5
U.S.C. App.).
Purpose: The Board will: (1) Conduct,
encourage, cooperate with, and assist
other appropriate public health
authorities, scientific institutions, and
scientists in the conduct of research,
investigations, experiments,
demonstrations, and studies relating to
the causes, diagnosis, treatment, control,
and prevention of physical and mental
diseases, and other impairments; (2)
assist States and their political
subdivisions in preventing and
suppressing communicable and noncommunicable diseases and other
preventable conditions and in
promoting health and well-being; and
(3) conduct and assist in research and
control activities related to injury. The
BSC, NCIPC makes recommendations
regarding policies, strategies, objectives,
and priorities; reviews progress toward
injury prevention goals; and provides
evidence in injury prevention-related
research and programs. The Board also
provides advice on the appropriate
balance of intramural and extramural
research, and the structure, progress,
and performance of intramural
programs. The Board is designed to
provide guidance on extramural
scientific program matters, including
the: (1) Review of extramural research
concepts for funding opportunity
announcements; (2) conduct of
Secondary Peer Review of extramural
research grants, cooperative agreements,
and contracts applications received in
response to funding opportunity
announcements as they relate to the
Center’s programmatic balance and
mission; (3) submission of secondary
review recommendations to the Center
Director of applications to be considered
for funding support; (4) review of
research portfolios, and (5) review of
program proposals.
Matters To Be Considered: The open
portion of the agenda will include
discussion on NCIPC Research Priorities
for Addressing Adverse Childhood
Experiences. The closed portion of the
agenda will focus on the Secondary Peer
Review of extramural research grant
applications received in response to
three Notice of Funding Opportunities
(NOFOs): (1) RFA–CE–21–001—
VerDate Sep<11>2014
17:13 Jun 22, 2021
Jkt 253001
‘‘Rigorous Evaluation of Policies for
their Impacts on the Primary Prevention
of Multiple Forms of Violence’’; (2)
RFA–CE–21–003—‘‘Grants to Support
New Investigators in Conducting
Research Related to Preventing
Interpersonal Violence Impacting
Children and Youth’’; and (3) RFA–CE–
21–004—‘‘Research Grants for
Preventing Violence and ViolenceRelated Injury (R01)’’; as well as PHS
2020 Omnibus Solicitation of the NIH,
CDC and FDA for Small Business
Innovation Research Grant Applications
(Parent SBIR [R43/R44] Clinical Trial
Not Allowed). Agenda items are subject
to change as priorities dictate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–13119 Filed 6–22–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10137 and CMS–
10174]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
32935
this collection of information, including
the necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions,
the accuracy of the estimated burden,
ways to enhance the quality, utility, and
clarity of the information to be
collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
August 23, 2021.
ADDRESSES: When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number: ll, Room C4–26–05,
7500 Security Boulevard, Baltimore,
Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, you may make your request
using one of following:
1. Access CMS’ website address at
website address at https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.html.
FOR FURTHER INFORMATION CONTACT:
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
Contents
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995 (the
PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
invited to send comments regarding our
burden estimates or any other aspect of
This notice sets out a summary of the
use and burden associated with the
following information collections. More
detailed information can be found in
each collection’s supporting statement
and associated materials (see
ADDRESSES).
CMS–10137 Solicitation for
Applications for Medicare
Prescription Drug Plan 2023 Contracts
CMS–10174 Collection of Prescription
Drug Data from MA–PD, PDP and
Fallout Plans/Sponsors for Medicare
Part D Payments
Under the PRA (44 U.S.C. 3501–
3520), federal agencies must obtain
AGENCY:
SUMMARY:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
William N. Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\23JNN1.SGM
23JNN1
]]>Agencies
[Federal Register Volume 86, Number 118 (Wednesday, June 23, 2021)]
[Notices]
[Pages 32934-32935]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-13119]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Board of Scientific Counselors, National Center for Injury
Prevention and Control, (BSC, NCIPC)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC
announces the following meeting for the Board of Scientific Counselors,
National Center for Injury Prevention and Control (BSC, NCIPC). This
meeting is partially open to the public. There will be 15 minutes
allotted for public comments at the end of the open session from 11:40
a.m., to 11:55 p.m., EDT.
DATES: The meeting will be held on July 29, 2021, from 10:00 a.m. to
12:00 p.m., EDT (OPEN); and from 12:30 p.m., to 4:15 p.m., EDT
(CLOSED).
ADDRESSES: Open Session: Webinar, Atlanta, Georgia. All participants
must register using the link provided to attend the open meeting:
https://dceproductions.zoom.us/webinar/register/wn_cz3nu0zfsg29fiojefau8q.
Closed Session: Teleconference.
FOR FURTHER INFORMATION CONTACT: Gwendolyn H. Cattledge, Ph.D.,
M.S.E.H., Deputy Associate Director for Science, NCIPC, CDC, 4770
Buford Highway NE, Mailstop S106-9, Atlanta,
[[Page 32935]]
GA 30341, Telephone: (770) 488-3953; Email: [email protected].
SUPPLEMENTARY INFORMATION: Portions of the meeting as designated above
will be closed to the public in accordance with provisions set forth in
Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of
the Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to Public Law 92-463 (5 U.S.C. App.).
Purpose: The Board will: (1) Conduct, encourage, cooperate with,
and assist other appropriate public health authorities, scientific
institutions, and scientists in the conduct of research,
investigations, experiments, demonstrations, and studies relating to
the causes, diagnosis, treatment, control, and prevention of physical
and mental diseases, and other impairments; (2) assist States and their
political subdivisions in preventing and suppressing communicable and
non-communicable diseases and other preventable conditions and in
promoting health and well-being; and (3) conduct and assist in research
and control activities related to injury. The BSC, NCIPC makes
recommendations regarding policies, strategies, objectives, and
priorities; reviews progress toward injury prevention goals; and
provides evidence in injury prevention-related research and programs.
The Board also provides advice on the appropriate balance of intramural
and extramural research, and the structure, progress, and performance
of intramural programs. The Board is designed to provide guidance on
extramural scientific program matters, including the: (1) Review of
extramural research concepts for funding opportunity announcements; (2)
conduct of Secondary Peer Review of extramural research grants,
cooperative agreements, and contracts applications received in response
to funding opportunity announcements as they relate to the Center's
programmatic balance and mission; (3) submission of secondary review
recommendations to the Center Director of applications to be considered
for funding support; (4) review of research portfolios, and (5) review
of program proposals.
Matters To Be Considered: The open portion of the agenda will
include discussion on NCIPC Research Priorities for Addressing Adverse
Childhood Experiences. The closed portion of the agenda will focus on
the Secondary Peer Review of extramural research grant applications
received in response to three Notice of Funding Opportunities (NOFOs):
(1) RFA-CE-21-001--``Rigorous Evaluation of Policies for their Impacts
on the Primary Prevention of Multiple Forms of Violence''; (2) RFA-CE-
21-003--``Grants to Support New Investigators in Conducting Research
Related to Preventing Interpersonal Violence Impacting Children and
Youth''; and (3) RFA-CE-21-004--``Research Grants for Preventing
Violence and Violence-Related Injury (R01)''; as well as PHS 2020
Omnibus Solicitation of the NIH, CDC and FDA for Small Business
Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical
Trial Not Allowed). Agenda items are subject to change as priorities
dictate.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-13119 Filed 6-22-21; 8:45 am]
BILLING CODE 4163-18-P
